KLRB1 and B-cell chronic lymphocytic leukemia: According to a previous report suggesting CD3+CD56+ NKT cells to be used for CLL therapy after in vitro augmentation [36], it will be important to evaluate TCR-Vβ-specific CD3+CD161+ cells for that purpose.